Baldwin & Lyons, Inc. Announces Second Quarter 2018 Earnings Release Date and Conference Call
CARMEL, Ind., June 21, 2018 (GLOBE NEWSWIRE) -- Baldwin & Lyons, Inc. (NASDAQ:BWINA) (NASDAQ:BWINB), today announced that management has scheduled its quarterly conference call for Wednesday, August 8, 2018, at 11:00 AM ET (New York time) to discuss results for the second quarter ended June 30, 2018. Results will be released prior to the opening of the financial markets on August 8, 2018, and will be available on the company's website at www.baldwinandlyons.com upon release.
To participate via teleconference, investors may dial 1-877-705-6003 (U.S./Canada) or 1-201-493-6725 (International or local) at least five minutes prior to the beginning of the call. A replay of the call will be available through August 15, 2018 by calling 1-844-512-2921 or 1-412-317-6671 and referencing passcode 13681025.
Investors and interested parties may also listen to the call via a live webcast, accessible on the company’s website via a link at the top of the main Investor Relations page. To participate in the webcast, please register at least fifteen minutes prior to the start of the call. The webcast will be archived on this site until February 8, 2019. The webcast may be accessed directly at: http://public.viavid.com/index.php?id=130200.
About the Company
Founded in 1930, Baldwin & Lyons, Inc. is a holding company for specialty property-casualty insurance subsidiaries. Through its subsidiaries, the company provides liability and workers compensation coverage for trucking and public transportation fleets, as well as coverage for trucking industry independent contractors. In addition, the company offers workers compensation coverage for a variety of operations outside the transportation industry. Baldwin & Lyons is headquartered in Carmel, Indiana.
Forward-looking statements in this report are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve inherent risks and uncertainties. Readers are encouraged to review the Company's annual report for its full statement regarding forward-looking information.
Investor Contact: William Vens
(317) 429-2554
investors@baldwinandlyons.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
U.S. FDA Approves Gilead Sciences' (Nasdaq: GILD) Antiviral Veklury (remdesivir) for the Treatment of COVID-19
